The David H. Koch Institute for Integrative Cancer Research and the BioMicro Center at the Massachusetts Institute of Technology are collaborating with Diagenode to automate assays for ChIP-seq and methyl-seq experiments.
The MIT researchers conducted "extensive tests" of Diagenode's SX-8G IP-Star system to validate its use in automating the design of epigenetic assays and next-gen sequencing library preparation. They are also using the system as a quality control for screening antibodies for ChIP-seq experiments.
Robert Urban, executive director of the Koch Institute, said in a statement that being able to automate customizable epigenetic assay design will support the "growing experimental needs of our oncology research community." In addition, Diagenode's SX-8G IP-Star system has "simplified the quality control of ChIP upfront of our ChIP-seq experiments."